JP2000504731A5 - - Google Patents

Download PDF

Info

Publication number
JP2000504731A5
JP2000504731A5 JP1997529647A JP52964797A JP2000504731A5 JP 2000504731 A5 JP2000504731 A5 JP 2000504731A5 JP 1997529647 A JP1997529647 A JP 1997529647A JP 52964797 A JP52964797 A JP 52964797A JP 2000504731 A5 JP2000504731 A5 JP 2000504731A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997529647A
Other languages
English (en)
Japanese (ja)
Other versions
JP4212112B2 (ja
JP2000504731A (ja
Filing date
Publication date
Priority claimed from GBGB9605044.8A external-priority patent/GB9605044D0/en
Priority claimed from GBGB9605045.5A external-priority patent/GB9605045D0/en
Priority claimed from GBGB9605046.3A external-priority patent/GB9605046D0/en
Application filed filed Critical
Priority claimed from PCT/US1997/003039 external-priority patent/WO1997030707A1/en
Publication of JP2000504731A publication Critical patent/JP2000504731A/ja
Publication of JP2000504731A5 publication Critical patent/JP2000504731A5/ja
Application granted granted Critical
Publication of JP4212112B2 publication Critical patent/JP4212112B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP52964797A 1996-02-23 1997-02-20 非ペプチジルバソプレッシンV1aアンタゴニスト Expired - Lifetime JP4212112B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US1221596P 1996-02-23 1996-02-23
US1218896P 1996-02-23 1996-02-23
US1214996P 1996-02-23 1996-02-23
GB9605044.8 1996-03-09
GB60/012,188 1996-03-09
GBGB9605044.8A GB9605044D0 (en) 1996-03-09 1996-03-09 Method and non-peptidyl agents for modulation of the vasopressin v1a receptor
GB9605045.5 1996-03-09
GB60/012,149 1996-03-09
GB9605046.3 1996-03-09
GBGB9605045.5A GB9605045D0 (en) 1996-03-09 1996-03-09 Method and non-peptidyl agents for modulation of the oxytocin receptor
GB60/012,215 1996-03-09
GBGB9605046.3A GB9605046D0 (en) 1996-03-09 1996-03-09 Method for antagonism of the tachykinin receptor with non-peptide agents
PCT/US1997/003039 WO1997030707A1 (en) 1996-02-23 1997-02-20 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS

Publications (3)

Publication Number Publication Date
JP2000504731A JP2000504731A (ja) 2000-04-18
JP2000504731A5 true JP2000504731A5 (https=) 2004-11-18
JP4212112B2 JP4212112B2 (ja) 2009-01-21

Family

ID=27547258

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52964797A Expired - Lifetime JP4212112B2 (ja) 1996-02-23 1997-02-20 非ペプチジルバソプレッシンV1aアンタゴニスト

Country Status (10)

Country Link
US (3) US6204260B1 (https=)
EP (1) EP0939632B1 (https=)
JP (1) JP4212112B2 (https=)
AT (1) ATE305781T1 (https=)
AU (1) AU1977997A (https=)
CA (1) CA2246753C (https=)
DE (1) DE69734321T2 (https=)
DK (1) DK0939632T3 (https=)
ES (1) ES2248840T3 (https=)
WO (1) WO1997030707A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258980T3 (es) 1999-08-16 2006-09-16 Revaax Pharmaceuticals Llc Composiciones farmaceuticas que comprenden acido clavulanico o derivados del mismo para el tratamiento de trastornos del comportamiento.
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
YU32702A (sh) 1999-11-04 2005-06-10 Ortho-Mcneil Pharmaceutical Inc. Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
ES2283589T3 (es) 2001-06-15 2007-11-01 Vicuron Pharmaceuticals, Inc. Compuestos biciclicos de pirrolidina.
ES2666188T3 (es) * 2001-10-12 2018-05-03 Azevan Pharmaceuticals, Inc. Antagonistas del v1a de vasopresina beta-lactámicos
AU2002359761A1 (en) * 2001-12-18 2003-06-30 Invenux, Inc. Antibiotic compounds
KR20120032574A (ko) * 2002-10-03 2012-04-05 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
WO2005035492A1 (en) * 2003-10-03 2005-04-21 Serenix Pharmaceuticals, Llc. 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS
KR20070011458A (ko) * 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
AU2013206201B2 (en) * 2005-03-22 2016-06-16 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
AU2006227199A1 (en) * 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
NZ563984A (en) * 2005-06-08 2011-11-25 Targegen Inc Methods and compositions for the treatment of ocular disorders
KR101523776B1 (ko) * 2005-07-19 2015-05-28 아제반 파마슈티칼스, 인코퍼레이티드 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US7691858B2 (en) * 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
BRPI1013901A2 (pt) * 2009-04-29 2019-09-24 Rexahn Pharmaceuticals Inc formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos
WO2012003436A1 (en) 2010-07-01 2012-01-05 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
NZ724718A (en) 2014-03-28 2023-04-28 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
WO2019055913A1 (en) 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US4665171A (en) 1985-07-17 1987-05-12 Harvard University Process and intermediates for β-lactam antibiotics
US4673737A (en) 1985-08-02 1987-06-16 Harvard University 7-acylamino-(or 7-amino)-3-trifluoromethylsulfonyloxy-1-carba(1-dethia)-3-cephem-4-carboxylic acids and esters thereof
DK429986A (da) 1985-09-09 1987-03-10 Otsuka Pharma Co Ltd 2-oxa-isocephemforbindelser
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) * 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
DK123488A (da) 1987-03-09 1988-09-10 Otsuka Pharma Co Ltd 2-oxa-isocephemforbindelser, praeparater indeholdende dem, og fremgangsmaader til fremstilling af dem
US5373089A (en) 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
US5068232A (en) 1990-04-10 1991-11-26 American Cyanamid Company Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them
US5521307A (en) * 1992-02-18 1996-05-28 Eli Lilly And Company Methods and compounds for the preparation of carbacephems
AU5587594A (en) * 1992-10-27 1994-05-24 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996016333A1 (en) * 1994-11-23 1996-05-30 Affymax Technologies, N.V. METHODS FOR SYNTHESIZING DIVERSE COLLECTIONS OF β-LACTAM COMPOUNDS
JPH11503728A (ja) * 1995-03-31 1999-03-30 シンファー ラボラトリーズ,インコーポレーティッド システイン・プロテイナーゼ阻害剤として有用な新規な4−置換−3−ペプチジル−アゼチジン−2−オン誘導体
AU5487496A (en) * 1995-05-03 1996-11-21 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs

Similar Documents

Publication Publication Date Title
JP2001503155A5 (https=)
JP2000511377A5 (https=)
JP2001503008A5 (https=)
JP2000512180A5 (https=)
JP2000515124A5 (https=)
JP2000510460A5 (https=)
JP2000510667A5 (https=)
JP2001500609A5 (https=)
JP2001502172A5 (https=)
JP2001505787A5 (https=)
JP2001501792A5 (https=)
JP2001500365A5 (https=)
JP2000512652A5 (https=)
JP2000514627A5 (https=)
JP2000512053A5 (https=)
JP2001502215A5 (https=)
JP2000513450A5 (https=)
JP2001501936A5 (https=)
JP2001502002A5 (https=)
JP2000507174A5 (https=)
JP2000506195A5 (https=)
JP2002514048A5 (https=)
JP2000503321A5 (https=)
JP2000515323A5 (https=)
JP2000515182A5 (https=)